Moreover, DNMT3A mutations facilitate disease progression in a CRISPR/Cas9 approach, which demonstrated DNMT3A loss leads to lethal disease in Jak2V617F-driven MPN mice model by loss of activation of enhancers and aberrant inflammatory signaling [48,51]. Here, DNMT3A is linked to myeloproliferative neoplasm.